Recent advances in peptide-based therapy for Type 2 diabetes and obesity

Peptides. 2021 Nov:145:170652. doi: 10.1016/j.peptides.2021.170652. Epub 2021 Sep 20.

Authors

J Michael Conlon¹, Peter R Flatt², Clifford J Bailey³

Affiliations

¹ Diabetes Research Group, School of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK. Electronic address: jmconlon1@gmail.com.
² Diabetes Research Group, School of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK.
³ Health and Life Sciences, Aston University, Birmingham B4 7ET, UK.

PMID: 34555424
DOI: 10.1016/j.peptides.2021.170652

No abstract available

Publication types

Editorial

MeSH terms

Animals
Anti-Obesity Agents / chemistry
Anti-Obesity Agents / pharmacology*
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / metabolism
Glucagon-Like Peptide-1 Receptor / agonists
Humans
Hypoglycemic Agents / chemistry
Hypoglycemic Agents / pharmacology*
Incretins / metabolism
Incretins / pharmacology
Obesity / drug therapy*
Obesity / metabolism
Obesity / surgery
Peptides / chemistry
Peptides / metabolism
Peptides / pharmacology*

Substances

Anti-Obesity Agents
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Incretins
Peptides